Title:
ＰＤ‐１及びＣＴＬＡ‐４との免疫応答性を有する二重特異性並びにその使用方法
Document Type and Number:
Japanese Patent JP6955507
Kind Code:
B2
Abstract:
The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
Inventors:
Johnson Leslie S.
Chichiri Grunad Lady
Shah Carpana
Ramote-Morse Ross
Moore Paul A.
Bombini Ezio
König Scott
Chichiri Grunad Lady
Shah Carpana
Ramote-Morse Ross
Moore Paul A.
Bombini Ezio
König Scott
Application Number:
JP2018549412A
Publication Date:
October 27, 2021
Filing Date:
December 12, 2016
Export Citation:
Assignee:
Macrogenics, Incorporated
International Classes:
C12N15/13; A61K39/395; A61P31/00; A61P35/00; A61P35/02; A61P37/04; C07K16/28; C07K16/46; C12N15/62
Domestic Patent References:
| JP2004512005A |
Foreign References:
| WO2015184203A1 | ||||
| CN104987421A |
Attorney, Agent or Firm:
Shiro Isoda